Active deal-making day for Boehringer, with two ADC collabs

German family-owned pharma major Boehringer Ingelheim has licensed antibody-drug conjugates ADC technology from Netherlands-based Synaffix, a Lonza (SWX: LONN) company.

This new partnership significantly bolsters Boehringer's ADC portfolio, driven by its subsidiary, NBE Therapeutics, to achieve the company’s aim of transforming the lives of people with cancer.

Under the terms of the agreement, Synaffix will provide access to its proprietary ADC technologies for an agreed but undisclosed number of targets. The first target was nominated upon signature, and additional targets will subsequently be nominated within a predefined timeframe. In addition to the upfront payment, Synaffix is eligible to receive potential additional milestone payments of up to $1.3 billion, plus additional royalty payments on net sales of resulting products.